Clinical study of Yiqi-Jiedu decoction combined with mesalazine sustained release granules for the patients with ulcerative colitis

Abstract

Objective To evaluate the effect of Yiqi-Jiedu decoction combined with mesalazine sustained release granules for the patients with ulcerative colitis (UC). Methods A total of 93 UC patients who met the inclusion criteria were divided into control group (46 cases) and study group (47 cases) according to the random number table method. The control group was treated with mesalazine sustained release granules orally. The treatment group added Yiqi-Jiedu decoction on the basis of the control group. Both groups were treated for 2 months. The level of plasma thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-Keto-PGF1α) and serum CRP, IL-1 and TNF-α were measured by ELISA, and the clinical effect was evaluated. Results The total effective rate was 95.7% (45/47) in the treatment group and 78.3% (36/46) in the control group. There was significant difference between the two groups (χ2=6.323, P=0.012). After treatment, the plasma TXB2 level in the treatment group was significantly lower than that in the control group (601.14 ± 13.31 pg/ml vs. 780.33 ± 16.54 pg/ml; t=57.619, P<0.01), and the plasma 6-Keto-PGF1α level was significantly higher than that in the control group (84.04 ± 11.39 pg/ml vs. 69.48 ± 10.21 pg/ml; t=6.487, P<0.01). After treatment, the level of CRP, IL-1 and TNF-α in the treatment group was significantly lower than those in the control group (t=15.457, 7.006 and 17.434, respectively, all Ps<0.01). Conclusions The Yiqi-Jiedu decoction combined with mesalazine sustained release granules can reduce the level of serum inflammatory cytokines in UC patients, reduce the level of plasma TXB2, and increase the level of plasma 6-Keto-PGF1α, so as to improve the clinical effectiveness. Key words: Colitis, ulcerative; Yiqi-Jiedu decoction; Inflammation; Therapies, investigational